Scott Tolan, MD
Interventional Cardiology · Kyle, TXNPI 1821313610
Payments from drug & device makers
Across 183 payments — averaging $77.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Shockwave Medical, Inc$2K
- Biotronik Inc.$1K
- Inari Medical, Inc.$1K
- Abbott$972
- Abiomed$820
- plus $5K from 25 others
What the payments were for
- Travel & lodging$3,00021%
- Food & beverage$11,05078%
- Education$1181%
- Gifts$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $3,555 |
| Shockwave Medical, Inc | 19 | $2,043 |
| Biotronik Inc. | 27 | $1,283 |
| Inari Medical, Inc. | 11 | $1,046 |
| Abbott | 16 | $972 |
| Abiomed | 8 | $820 |
| Penumbra, Inc. | 7 | $741 |
| Teleflex LLC | 4 | $394 |
| Johnson & Johnson | 7 | $394 |
| Heartflow, Inc. | 4 | $342 |
| Amgen | 16 | $313 |
| Acist Medical Systems, Inc. | 2 | $300 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Angiodynamics, Inc. | 4 | $246 |
| Philips North America LLC | 3 | $235 |
| Novartis | 10 | $224 |
| AstraZeneca | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Chiesi USA, Inc. | 2 | $115 |
| Scpharmaceuticals Inc. | 3 | $114 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $110 |
| Bayer | 1 | $97 |
| Pfizer | 4 | $76 |
| Merck | 1 | $75 |
| Medtronic | 3 | $65 |
| Lantheus Medical Imaging, Inc. | 2 | $48 |
| Reflow Medical Inc | 1 | $39 |
| Boehringer Ingelheim | 1 | $34 |
| Cardiva Medical, Inc. | 1 | $23 |
| Stryker | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$3,080
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,728
- Impella$773
- FLOWTRIEVER CATHETER, S$757
- CT THROMBECTOMY SYSTEM KIT$757
- Indigo System$664
- Orsiro Mission$351
- FFRct$288
- CVI SYSTEMS$284
- XARELTO$250
- AlphaVac$190
- DRAGONFLY OPSTAR$164
- MANTA$150
- Diamondback Peripheral$142
- TURNPIKE CATHETER$140
- Lasers$135
- DISEASE STATE$125
- FARXIGA$125
- Ultreon$124
- ONPATTRO$123
How this compares
$14,244 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $80,978 |
| JardianceEmpagliflozin | 45 | $60,410 |
| EntrestoSacubitril/Valsartan | 54 | $54,348 |
| Repatha SureclickEvolocumab | 74 | $43,347 |
| FarxigaDapagliflozin Propanediol | 23 | $22,929 |
| XareltoRivaroxaban | 19 | $21,809 |
| Ranolazine ErRanolazine | 25 | $2,666 |
| Olmesartan Medoxomil | 77 | $1,474 |
| Atorvastatin Calcium | 120 | $1,433 |
| Rosuvastatin Calcium | 93 | $1,252 |
| Metoprolol Succinate | 102 | $1,108 |
| Losartan Potassium | 89 | $917 |
| Spironolactone | 110 | $902 |
| Nifedipine ErNifedipine | 41 | $875 |
| Carvedilol | 61 | $709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $80,97874 claims |
| Boehringer IngelheimJardiance | $34 | $60,41045 claims |
| NovartisEntresto | $224 | $54,34854 claims |
| AstraZenecaFarxiga | $125 | $22,92923 claims |
| Johnson & JohnsonXarelto | $394 | $21,80919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Kyle
- Vamsi KrishnaKyle$2.2M
- Peter MonteleoneKyle$1.1M
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.